The retail cannabis industry, dispensaries, consumer packaged goods brands, delivery services, and online ordering platforms, is the public face of the commercial THC economy. It is where cultivation and processing meet the consumer; where plant material and processed extracts become branded edibles, pre-rolls, vape cartridges, tinctures, and topicals; and where the deliberate marketing strategies of an industry seeking habitual customers shape how millions of Americans relate to intoxication. For the biblically responsible investor, the retail THC industry represents not an abstraction but a specific commercial enterprise: companies producing and distributing products whose purpose is to deliver THC, a psychoactive compound, to consumers at scale.
The scale and velocity of the retail cannabis industry’s growth are remarkable. In 2012, there were no legal recreational cannabis dispensaries anywhere in the United States. By 2024, more than 15,000 licensed cannabis retail locations operated across 24 states and the District of Columbia, with annual U.S. retail sales exceeding $33 billion. The industry has deployed sophisticated consumer marketing, branding, influencer partnerships, loyalty programs, and product innovation, to normalize cannabis consumption and build recurring customer relationships. The edibles market alone has expanded to include chocolate bars, gummy candies, beverages, and infused cooking ingredients engineered to appeal to the broadest possible consumer base, including those who might be deterred by traditional smoked cannabis.
This normalization strategy is not ideologically neutral. When companies name cannabis gummies after candy brands, market products in packaging indistinguishable from confectionery, and build retail experiences modeled on the Apple Store or Starbucks, they are making a deliberate bet that cultural normalization is commercially valuable - and they are right. But normalization has consequences. It erodes the social signals that historically deterred experimentation among young people, reduces parental awareness, and facilitates household access by minors through product formats difficult to distinguish from non-intoxicating alternatives. The retail cannabis industry is not a passive distributor of a legal product. It is an active architect of a culture of intoxication.
Inspire screens Cannabis (Retail THC) violators as a principled application of biblical values to an industry whose commercial model - and whose documented effects on mental health, adolescent development, and human flourishing - stands in tension with the responsibilities of biblically responsible stewardship.
As of the 2026 research update, Inspire Insight cites 122 instances of Cannabis (Cultivation/Processing) violators matching this definition.
Total U.S. cannabis retail sales in 2023—a more than 1,000% increase from a decade prior—making the American cannabis retail sector one of the fastest-growing consumer industries in the country.
Estimated Americans who met criteria for Cannabis Use Disorder and sought treatment in 2022—a figure that has risen sharply alongside the expansion of the legal retail market (SAMHSA).**
Though cannabis is never referenced in Scripture, the Bible offers a comprehensive and internally consistent framework for assessing the moral weight of an industry whose primary commercial product is a substance engineered to alter the human mind. That framework is built on four pillars: the body and mind as the dwelling of the Holy Spirit, the imperative of sobriety and self-control, the call to love one’s neighbor as oneself, and the faithful stewardship of all that God has entrusted to His people.
Paul’s teaching that the believer’s body is not merely their own but is the purchased possession of God, a living sanctuary of the Holy Spirit, establishes the foundational biblical principle for evaluating any substance that deliberately alters the mind God created. THC, the psychoactive compound at the center of the retail cannabis industry’s commercial offering, does not act peripherally: it binds directly to cannabinoid receptors throughout the brain, disrupting the very cognitive and emotional faculties through which believers worship, serve, reason, and love. An industry built on the retail distribution of THC is an industry built on the sale of cognitive impairment.
Scripture’s instruction to honor God with the body is not a peripheral concern—it is presented as an act of worship. The commercial cannabis industry profits from a product whose primary mode of consumption is the deliberate alteration of the mind and body that God created, redeemed, and indwells.
The New Testament employs the Greek word nēphō throughout to describe the sobriety Scripture commands - a word that encompasses not merely abstinence from intoxicants but clear-headedness, alertness, and the full possession of one’s cognitive faculties. THC is commercially produced for precisely the opposite: the voluntary induction of an altered state of consciousness. Unlike alcohol, which Scripture acknowledges can be used without sin in moderation (John 2:1–11; Psalm 104:14–15), cannabis as a commercial product has no analogous moderate-use precedent in Christian thought or practice, its psychoactive effect begins at the first meaningful dose and is the product’s entire commercial purpose.
The principle in 1 Corinthians 6:12 (‘I will not be dominated by anything’) is particularly incisive in the context of the cannabis industry. Cannabis Use Disorder (CUD), formally recognized in the DSM-5, affects approximately 9% of all cannabis users (NIDA). That figure rises to 17% among those who begin use in adolescence and to 25–50% among daily users (NIDA). For a substantial portion of cannabis consumers, what is marketed as recreational choice becomes a chemical dependency that redirects the will’s allegiance away from Christ’s lordship and toward a substance.
Biblical ethics are never purely individualistic. The command to love one’s neighbor as oneself (Matthew 22:39) extends to how believers deploy economic power and financial capital. The cannabis industry disproportionately harms young people, whose developing brains are uniquely and measurably vulnerable to THC’s psychoactive and psychosis-inducing effects. A landmark 2019 study in The Lancet Psychiatry (Di Forti et al., 2019) found that daily users of high-potency cannabis were five times more likely to develop a psychotic disorder than non-users; a risk concentrated precisely among the adolescent and young-adult populations the industry most actively recruits through branding, social media, and accessible retail.
A complete biblical treatment of the commercial cannabis industry must acknowledge the medical dimension. Cannabis-derived medications, most notably cannabidiol (CBD), which is non-psychoactive, and in certain formulations low-dose THC, have demonstrated genuine therapeutic efficacy for conditions including drug-resistant epilepsy (Epidiolex, FDA-approved in 2018), chronic pain, and chemotherapy-induced nausea. The compassionate use of any plant-derived compound for genuine medical healing is consistent with Scripture’s affirmation of creation’s goodness and the call to care for the sick and suffering.
The retail cannabis industry in the United States traces its modern origins to California’s Proposition 215, passed by voters in November 1996. While the measure primarily authorized medical cultivation and distribution, the dispensary model that emerged in its wake, storefronts offering cannabis to patients with a physician’s recommendation, created the first legal consumer-facing cannabis retail experience in American history. The early dispensaries were informal, often operating in legal gray areas, resembling a hybrid between a pharmacy and a neighborhood shop. Yet they established a template: a dedicated retail location, product selection, and a customer relationship built around cannabis as a consumer product.
The medical dispensary era (1996–2012) was characterized by rapid proliferation in permissive states, most notably California, where looseness in the medical recommendation system effectively created de facto recreational access for anyone willing to visit a participating physician. By the early 2010s, Los Angeles alone had more than 1,000 dispensaries (more than the city’s McDonald’s, Starbucks, and 7-Elevens combined). The product offering was predominantly flower, with limited edibles and concentrates. Branding was minimal; the consumer relationship transactional. That would soon change dramatically.
The transformation of cannabis from a medical niche to a mainstream consumer industry was catalyzed by Colorado’s Amendment 64 and Washington State’s Initiative 502, both passed by voters in November 2012. These measures legalized cannabis for adult recreational use and created the first fully licensed recreational retail frameworks in the world. Colorado’s first recreational dispensaries opened on January 1, 2014, to lines stretching around the block, a cultural moment signaling cannabis had crossed a threshold from counterculture to consumer product. The revenue implications were immediate: Colorado collected more than $76 million in cannabis excise taxes in its first year of recreational sales.
In the decade following Colorado and Washington’s legalization, the retail cannabis product landscape underwent a transformation without parallel in any comparable consumer category. Flower (the traditional smoked form) was joined by an explosion of new product categories: precisely dosed edibles (gummies, chocolates, baked goods, beverages), vape cartridges, tinctures, topicals, transdermal patches, and high-potency concentrates (wax, shatter, rosin, distillate). Each category represented an innovation designed to expand the consumer base, reduce barriers to entry, increase consumption frequency, or all three. Cannabis-infused beverages positioned themselves as a ‘sober-curious’ alternative to alcohol; edibles appealed to consumers who rejected smoking; vape cartridges offered discreet, odorless consumption usable in nearly any social setting.
The branding and marketing sophistication of the retail cannabis industry has grown in proportion to its revenue ambitions. Early dispensaries gave way to professionally designed retail concepts with carefully curated environments, trained sales staff (‘budtenders’), loyalty programs, and brand identities developed by major consumer goods consultancies. Celebrity investment and endorsement became a significant marketing vehicle: Jay-Z launched the premium cannabis brand Monogram in 2020, Snoop Dogg has been associated with multiple cannabis ventures, and a roster of athletes, musicians, and entertainment figures have attached their names to brands targeting precisely their fan demographics. Social media platforms, despite nominal restrictions on cannabis advertising, became central distribution channels for cannabis brand content, and assisted in normalizing consumption to audiences that included substantial numbers of minors.
The edibles market attracted particular scrutiny from public health authorities. Regulators in multiple states documented cannabis-infused products whose packaging was designed to closely resemble popular candy and snack brands - a practice critics described as deliberate targeting of children. Emergency department visits by children who had accidentally consumed cannabis edibles increased sharply in states following legalization (AAPCC, 2022), with poison control centers reporting significant year-over-year increases in cannabis-related pediatric ingestion cases. The American Academy of Pediatrics specifically cited edible cannabis products as a pediatric safety concern, noting that their candy-like appearance and portability made accidental ingestion by children substantially more likely than traditional smoked cannabis (AAP, 2020).
The financial and regulatory environment for U.S. retail cannabis operators is shaped by the industry’s continued federal illegality. Internal Revenue Code Section 280E, which disallows ordinary business deductions for companies trafficking in Schedule I or II controlled substances, creates a punishing tax burden for cannabis retailers, who may face effective tax rates of 60–70% on gross profit. The lack of access to FDIC-insured banking has forced many retailers to operate as cash-intensive businesses, creating security risks and limiting access to capital. The SAFE Banking Act, which would extend federal banking protections to state-legal cannabis businesses, has passed the House of Representatives multiple times but repeatedly stalled in the Senate, leaving the industry in a structurally anomalous position: a multi-billion-dollar consumer industry denied access to the basic financial infrastructure available to every other legal business in America.
As of 2025, more than 24 states and the District of Columbia have legalized recreational cannabis, and more than 38 states have some form of medical cannabis program. The major publicly traded retail operators, Curaleaf Holdings, Green Thumb Industries, Trulieve Cannabis, and Ayr Wellness among them, are multi-state operators with vertically integrated business models spanning cultivation, processing, and retail. The industry’s trajectory continues toward federal rescheduling under the Controlled Substances Act, an outcome that would dramatically expand access to capital markets, banking, and interstate commerce - and with it, the commercial scale and marketing reach of an industry already reshaping American consumer culture.
Inspire’s definition for Cannabis (Retail THC) captures companies at the consumer-facing endpoint of the commercial THC supply chain: those that produce retail cannabis products containing THC or that distribute such products to end consumers. This encompasses licensed dispensaries, cannabis consumer packaged goods brands (edibles, vapes, tinctures, topicals, concentrates), and delivery platforms whose commercial offering includes THC-containing products. The definitional anchor is the presence of THC, the psychoactive compound, in the retail product. Products that contain CBD but no THC, or that fall below federally legal hemp THC thresholds (0.3% by dry weight), do not automatically trigger this screen.
The relationship between the Cannabis (Retail THC) screen and the Cannabis (Cultivation/Processing) screen reflects the vertical integration of the modern cannabis industry. Many large cannabis operators cultivate, process, and retail cannabis within a single corporate structure, meaning they may appear in both screening categories. A company that is purely a licensed retail dispensary purchasing wholesale cannabis from third-party cultivators would appear only in the Retail THC category. A company that cultivates and processes cannabis but sells exclusively through wholesale channels would appear only in the Cultivation/Processing category. Vertically integrated operators appear in both.
Particular attention is given to product format and marketing practices when evaluating potential Retail THC violators. The deliberate proliferation of cannabis products in formats designed to maximize consumer appeal, including candy-adjacent edibles, brand-name vape cartridges, and retail environments engineered to normalize and encourage consumption, is considered in Inspire’s assessment. Companies that deploy these practices in ways that specifically target or normalize cannabis consumption among youth represent a heightened concern under Inspire’s BRI framework. Research methodology draws on state cannabis control authority licensing databases, company investor filings, and direct company website verification, with Bloomberg and Sustainalytics serving as primary data aggregation tools.
Cutout: Cannabis Industry Cutout
The commercial cannabis industry presents a human cost that is at once more diffuse and more insidious than that of tobacco. It lacks tobacco’s grim mortality statistics, cannabis is not linked to lung cancer at tobacco’s scale, nor does it carry the same direct cardiovascular burden. But its human cost is real, growing, and increasingly well-documented: a generation of young people exposed to potency levels and product formats that bear no resemblance to what prior eras experienced; rising rates of Cannabis Use Disorder; a well-established and alarming link between high-potency cannabis and psychotic disorders; and an industry whose commercial logic, like tobacco’s before it, depends on cultivating habitual users as early as possible.
Perhaps the most urgent and underappreciated human cost of the modern cannabis industry is its impact on mental health, particularly among young and heavy users. A growing body of peer-reviewed research has established a dose-dependent relationship between cannabis use and psychotic disorders. A 2019 study in The Lancet Psychiatry (Di Forti et al.), drawing on data from eleven sites across Europe and Brazil, found that daily users of high-potency cannabis were five times more likely to develop a psychotic disorder than non-users. In areas where high-potency cannabis constituted a greater share of the market, the incidence of psychosis was correspondingly higher, a finding that directly implicates the deliberate potency escalation strategy of modern cannabis companies.
Beyond psychosis, cannabis use is associated with measurable increases in anxiety and depression, particularly among adolescent users. Longitudinal studies have found that adolescents who use cannabis regularly are significantly more likely to develop depressive disorders in early adulthood than non-using peers, with the effect most pronounced among heavy users. The American Academy of Pediatrics has repeatedly and explicitly advised against any cannabis use during adolescence, citing risks of impaired neurodevelopmental outcomes, reduced academic achievement, and increased vulnerability to psychopathology (AAP, 2020).
The human brain does not reach full developmental maturity until approximately age 25. THC’s principal mechanism of action, binding to cannabinoid receptors that play a critical regulatory role in neural development, means that cannabis exposure during adolescence does not merely produce transient intoxication but potentially disrupts the developmental trajectory of the brain itself. Research has found that adolescents who use cannabis heavily show measurable differences in brain structure and function compared to non-users, including in regions associated with memory, decision-making, and emotional regulation (NIDA). These are not theoretical risks; they are empirically measured outcomes with consequences that can persist into adulthood.
The commercial cannabis industry has been aware of these risks for years. That awareness has not moderated commercial strategies. THC potency has continued to climb, product formats have diversified to maximize appeal and consumption frequency, and the industry has consistently resisted regulatory measures that would constrain commercial growth. The average THC concentration in cannabis flower increased from approximately 4% in 1995 to over 12% by 2014 (ElSohly et al., 2016); modern concentrates routinely test at 80–90% THC (NIDA) - a potency increase with no parallel in any other legal consumer intoxicant.
Cannabis Use Disorder (CUD), formally recognized in the DSM-5, is characterized by a problematic pattern of cannabis use leading to clinically significant impairment or distress. Approximately 9% of all cannabis users develop CUD, a figure that rises to 17% among those who begin using in adolescence and to 25–50% among daily users (NIDA). Between 2001 and 2013, cannabis use disorder among American adults increased by 74% (JAMA Psychiatry). As the market has expanded since 2013, with recreational legal frameworks added in more than twenty additional states, that trend has continued apace. The industry that supplies increasingly potent products to an increasingly accessible retail network is not a passive participant in this trend. It is its primary driver.
The normalization of cannabis use carries public safety costs that extend beyond individual health outcomes. The National Highway Traffic Safety Administration has identified marijuana as the second most commonly detected substance, after alcohol, in fatally injured drivers.
Marijuana-involved traffic fatalities in Colorado increased 92% in the five years following recreational legalization (Colorado MED, 2022), and Washington State saw similar patterns. Approximately 12 million Americans reported driving under the influence of marijuana at least once in 2021 (NHTSA). The economic costs of cannabis use, healthcare utilization, lost workplace productivity, and impaired educational outcomes, are less fully quantified than those of alcohol or tobacco, in part because systematic data collection has lagged legalization timelines, but the emerging evidence is consistent with a significant and growing burden on communities.
From a BRI perspective, the human cost of cannabis cannot be neatly separated from the commercial strategies of the industry that profits from it. Every cannabis psychosis, every impaired adolescent brain, every case of Cannabis Use Disorder represents a loss, a diminishment of the life of an image-bearer of God, someone uniquely formed by His hand, purposed for His glory, and loved by Christ to the point of His death and resurrection. Every investor who financially supports that industry through capital allocation shares, in some measure, in the consequences of those choices.
The Bible does not name cannabis, but its teachings speak directly and compellingly to an industry whose commercial purpose is the production and distribution of a substance that impairs the mind, undermines self-control, and carries documented harm to the vulnerable. The following biblical principles together inform Inspire’s approach to this screening category:
For Inspire, screening the cannabis industry is not a political statement about drug policy or a judgment about the legal status of cannabis under state law. It is a principled commitment to deploying capital in ways consistent with the biblical vision of human flourishing: sober-minded, self-controlled, honoring to God, and genuinely concerned for the well-being of one’s neighbors-especially the most vulnerable.
Inspire's engagement with public companies is part of its Biblically Responsible Investing (BRI) philosophy and aims to promote biblical values through corporate dialogue. Engagement outcomes are not guaranteed and may not directly impact investment returns. Shareholder advocacy is based on Inspire's internal values and may not reflect those of every investor.
**Inspire Investing, LLC serves as the investment adviser to certain proprietary ETFs used in Inspire portfolios. Inspire receives management fees from these ETFs, creating a potential conflict of interest. Inspire seeks to mitigate this conflict through policies and procedures that ensure recommendations are made in clients’ best interests and consistent with their unique goals and risk profiles. Additional details can be found in Inspire’s Form ADV Part 2A.
Inspire's BRI criteria reflect our firm's convictions as described in Form ADV Part 2A and may not be suitable for all investors.
Advisory services are offered through Inspire Investing, LLC, a Registered Investment Adviser with the SEC. All expressions of opinion are subject to change without notice and are provided for informational purposes only. Nothing in this article should be construed as an offer, solicitation, recommendation, or endorsement of any particular security, strategy, or investment product. Investing involves risk, including the potential loss of principal. . Please consult your financial advisor before making any investment decision.
This content is provided for educational and informational purposes only and should not be construed as individualized investment advice. Inspire Investing does not know your personal financial situation and this material should not be used as a basis for any specific investment decision
Data referenced from the National Survey on Drug Use and Health (SAMHSA), Grand View Research, MJBizDaily, the National Institute on Drug Abuse (NIDA), and other publicly available sources are believed to be reliable but have not been independently verified by Inspire Investing. References to third-party organizations do not constitute endorsement or approval of their methodologies or viewpoints.
Inspire Investing integrates biblical principles into its investment philosophy through a Biblically Responsible Investing (BRI) approach. This value-based methodology reflects Inspire’s interpretation of Scripture and may not align with the views or beliefs of all investors. Inspire does not claim divine endorsement of any investment outcome or specific company behavior.
